This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Johnson & Johnson Beats Earnings and Will Lift Dow, Biotech: StockTwits

NEW YORK (TheStreet) -- Johnson & Johnson (JNJ - Get Report) gave the markets a reason to continue Monday's rally. The healthcare giant announced results Tuesday morning that beat Wall Street consensus estimates for earnings per share and revenue.

Wow $jnj crushed it. Congrats longs

-- Aleks (@NYCStox) Apr. 15 at 07:48 AM

The results confirmed the growing bullishness on Johnson & Johnson on

Plus, many investors said that J&J's quarterly results, particularly the growth of its pharmaceutical business, could help lift the beaten-down biotech sector. iShares Nasdaq Biotechnology ETF (IBB) has lost 5.2% in the past five days.

$RNN Beat on earnings by $JNJ. Let's see some of the love extend to the Bios today. Best of mornings all! :-) Go $RNN.

-- Lynn (@Stocktok) Apr. 15 at 08:06 AM

Johnson & Johnson reported first quarter earnings per share of $1.54 on $18.1 billion in sales. That topped analysts' EPS estimates by 6 cents and sales predictions by $100 million, according to the Analyst Ratings Network. It was the top-trending ticker on early Tuesday morning.

The company increased its full year EPS guidance to between $5.80 to $5.90, excluding special items. The new midpoint of the guidance topped consensus calls for $5.83.

Much of J&J's growth was fueled by medicines. Pharmaceutical sales grew 12.2%, discounting the impact of currency. Drugs to treat arthritis, schizophrenia and myeloma buoyed results. The consumer business actually weighed on growth.

Shares opened more than 2% higher to top $97 per share. Many investors called for more gains. Sentiment on Johnson & Johnson stood at around 86% bullish before the open, according to StockTwits' analytics.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JNJ $94.76 0.00%
AAPL $110.78 0.00%
FB $94.01 0.00%
GOOG $641.47 0.00%
TSLA $246.15 0.00%


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs